BioNTech (BNTX) is presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Highlights include: executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches; BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology backbone for the company’s combination strategy targeting a broad range of indications; progressing development of BNT327/PM8002 with initiation of global clinical trials with registrational potential in first-line small cell lung cancer and non-small cell lung cancer; advancing BNT327/PM8002 combination strategy with initiation of a second antibody drug conjugate combination trial; additional ADC-combination trials planned to be initiated in 2025; progress in mRNA cancer immunotherapy portfolio with multiple randomized trial read-outs of personalized and off-the-shelf candidates expected in 2025 and 2026.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech initiated with a Buy at Truist
- NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
- BioNTech to pay $467M in settlement agreement with University of Pennsylvania
- BioNTech to pay $791.5M in settlement agreement with the NIH
- BioNTech Settles Royalty Dispute with NIH for $791.5 Million